Biologics: the good, the bad and the oh so expensive
Biologics are therapeutics that target specific components of the immune system. They are characterised by unpronounceable generic names (alemtuzumab, eculizumab, blinotumomab, pembrolizumab). These medications have revolutionised the treatment of several immune-mediated disorders: including rheumatoid arthritis, inflammatory bowel diseases, psoriasis, lymphoma, lung, breast, ovarian and other cancers, and macular degeneration, and are widely used in a range of clinical disciplines.